A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome

Prader-Willi Syndrome Clinical Trial

Official title:

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05098509
• Other study ID #: SCOUT-015
• Status: Terminated
• Phase: Phase 2/Phase 3
• Start date: April 13, 2022
• Est. completion date: October 31, 2022

Study information

• Verified date: September 2023
• Source: Radius Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was a study investigating RAD011 in participants diagnosed with Prader-Willi Syndrome (PWS). The primary objective of the Phase 2 part of this study was to assess the safety and tolerability of multiple dose levels of RAD011 in order to select 1 or 2 dose level(s) for further evaluation in the Phase 3 part of the study. In Phase 3, the primary objective was to assess the effect of RAD011 on hyperphagia-related behavior in participants with PWS.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: October 31, 2022
• Est. primary completion date: October 6, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years to 65 Years

Eligibility

Inclusion Criteria:

• Males and females between 8 and 65 years of age (inclusive) at Screening.

• Genetically confirmed diagnosis of PWS. Documentation of genetically confirmed diagnosis of PWS is acceptable.

• The same caregiver is available to complete the questionnaire throughout the duration of the study.

• After completion of the Tolerability period, participants will have a mean Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score =13 and a decrease of HQ-CT score no more than 7 during Tolerability (run-in) period.

• If receiving growth hormone, psychotropic therapy, metabolic treatments that could affect appetite (including metformin), and other treatment including thyroid hormone, must be on the same medication and dose for at least 90 days prior to consent/assent

Exclusion Criteria:

• Known use of cannabis or cannabinoid containing products (including topical products) within 90 days prior to consent/ assent.

• Use of prescription or over-the-counter weight loss agents within 90 days prior to consent/assent.

• Implementation of new food or environmental restrictions within 90 days of consent/ assent.

• If living in a group home, participant spends less than 25 waking hours with their caregiver per week.

• Uncontrolled chronic conditions (diabetes, sleep apnea, etc.) as determined by the Investigator.

Related Conditions & MeSH terms

• Prader-Willi Syndrome
• Syndrome

Intervention

Drug:
• RAD011
Cannabidiol Oral Solution (containing synthetic cannabidiol)
• Placebo
Matching Placebo for RAD011

Locations

Country	Name	City	State
United States	Maimonides Medical Center	Brooklyn	New York
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	Research Institute of Dallas	Dallas	Texas
United States	University of Iowa	Iowa City	Iowa
United States	Children's Hospital Los Angeles	Los Angeles	California
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Rady Children's Hospital	San Diego	California
United States	MultiCare Institute for Research & Innovation	Tacoma	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Radius Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline to Week 34 in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Questionnaire	The HQ-CT measures hyperphagia by Prader-Willi syndrome (PWS)-specialized clinicians. The HQ-CT generates a score ranging from 0 to 36, where a higher score represents more severe abnormal food related behaviors.; The change from baseline was calculated from two time points as the value at the later time point minus the value at the earlier time point.	Baseline, Week 34
Secondary	Change From Baseline to Week 34 in Prader-Willi Syndrome (PWS)- Associated Irritability Using the Aberrant Behavior Checklist (ABC) Questionnaire - Irritability Subscale (ABC-I)	The ABC questionnaire is an informant-rated questionnaire assessing severity of behavioral symptoms. The Irritability subscale of the ABC covers symptoms such as agitation, aggression, meltdowns, and self-harm. The ABC-I contains 15 items and each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). The total score is the sum of individual items scores which ranges from 0 (no problem) to 45 (severe problem), with higher score indicating more severe condition.	Baseline, Week 34
Secondary	Change From Baseline to Week 34 in Hyperphagia as Measured by the Clinician Global Impression of Change (CGI-C)	The CGI-C of hyperphagia is a single-item, clinician-rated measure, assessing the clinician's impression about changes in the patient's hyperphagia condition since the start of taking the study medication at the initiation of the Tolerability Period. The CGI-C of hyperphagia utilizes a 5-point response scale: 1=Much better; 2=A little better; 3=No change; 4=A little worse; 5=Much worse. Higher scores mean a worse outcome.	Baseline, Week 34
Secondary	Change From Baseline to Week 34 in Hyperphagia as Measured by the Clinician Global Impression of Severity (CGI-S)	The CGI-S of hyperphagia is a single-item, clinician-rated measure, assessing the clinician's impression of the severity of a patient's hyperphagia condition. The CGI-S of hyperphagia utilizes a 5-point response scale: 1=None; 2=Mild; 3=Moderate; 4=Severe; 5=Very Severe. Higher scores mean a worse outcome.	Baseline, Week 34